Emotional toll of diabetes ‘needs more recognition’

  • Image copyright – Getty Images – – – – Many people living with diabetes are struggling with related emotional problems – an issue that needs support and recognition, a charity says.Diabetes UK surveyed 8,500 people about diabetes and how it affected their daily life.Three in five said their condition made…
  • “Life-changingThe number of people diagnosed with diabetes – type 1 and type 2 – is on the rise.
  • According to Diabetes UK, about 700 people are diagnosed every day.And it’s a life-changing diagnosis.Those affected often have to check their blood sugars up to 10 times a day and plan their meal breaks – and what they will be eating – factoring in any exercise they may be doing….
  • It is usually seen in adults and is often associated with obesity – It is important to keep blood sugar under control to prevent health complications – Symptoms of type 2 diabetes include – feeling very thirsty, passing urine more often than usual, particularly at night and feeling very tired…
  • “We want to see a system where specialist support – from people who understand diabetes – is made available to those who need it.

Living with diabetes can lead to significant emotional problems, a survey finds.
Continue reading “Emotional toll of diabetes ‘needs more recognition’”

‘Monumental U-turn’ on cancer drug

A pioneering cancer drug deemed too expensive will now be offered on the NHS in England

  • It is the result of a confidential deal between the health service and the drug company Roche.Kadcyla, the undiscounted cost of which had been £90,000 per patient, adds an average of six months of life to women with a form of terminal breast cancer.Campaigners have praised the “monumental” U-turn, which will benefit about 1,200 women a year.
  • “Tough negotiation and flexibility between the NHS and Roche means both patients and taxpayers are getting a good deal,” said NHS England chief executive Simon Stevens.Cost-effectiveness testKadcyla, a combination of two drugs, is used to treat people with HER2-positive tumours that have spread to other parts of the body and cannot be surgically removed.Scotland decided in April to pay for the drug, but it had been deemed too expensive by the rest of the UK.In order for a drug to be approved by the regulatory body, the National Institute for Health and Clinical Excellence (NICE), it has to pass a cost-effectiveness test.
  • The full price drug worked out at £166,000 for every “quality adjusted life year” of good health.
  • That is in line with other drugs that extend the life of terminally ill patients.DelightedRichard Erwin, general manager at Roche, said: “Close collaboration between Roche, NHS England and NICE has resulted in NICE recommending Kadcyla as a cost-effective treatment.
  • “A petition by the charity to get Kadcyla funded had amassed more than 115,000 signatures in less than a month.Gunes Kalkan, from Breast Cancer Care, said: “This U-turn decision is monumental.

Breast cancer drug Kadcyla should now become routine treatment in the UK.
Continue reading “‘Monumental U-turn’ on cancer drug”

‘Monumental U-turn’ on cancer drug

  • It is the result of a confidential deal between the health service and the drug company Roche.Kadcyla, the undiscounted cost of which had been £90,000 per patient, adds an average of six months of life to women with a form of terminal breast cancer.Campaigners have praised the “monumental” U-turn, which will benefit about 1,200 women a year.
  • “Tough negotiation and flexibility between the NHS and Roche means both patients and taxpayers are getting a good deal,” said NHS England chief executive Simon Stevens.Cost-effectiveness testKadcyla, a combination of two drugs, is used to treat people with HER2-positive tumours that have spread to other parts of the body and cannot be surgically removed.Scotland decided in April to pay for the drug, but it had been deemed too expensive by the rest of the UK.In order for a drug to be approved by the regulatory body, the National Institute for Health and Clinical Excellence (NICE), it has to pass a cost-effectiveness test.
  • The full price drug worked out at £166,000 for every “quality adjusted life year” of good health.
  • That is in line with other drugs that extend the life of terminally ill patients.DelightedRichard Erwin, general manager at Roche, said: “Close collaboration between Roche, NHS England and NICE has resulted in NICE recommending Kadcyla as a cost-effective treatment.
  • “A petition by the charity to get Kadcyla funded had amassed more than 115,000 signatures in less than a month.Gunes Kalkan, from Breast Cancer Care, said: “This U-turn decision is monumental.

Breast cancer drug Kadcyla should now become routine treatment in the UK.
Continue reading “‘Monumental U-turn’ on cancer drug”